Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies supporting the application had a mysterious difference in outcomes. Further analysis of virologic failures is under way, says lead investigator.
You may also be interested in...
Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.
Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
Lead investigator from Phase III trials says Edurant could be viable option in about half of treatment-naïve patients, points out safety advantages.
Gilead's Next HIV Triple-Combo Pill May Prevent Generic Erosion; Can It Prevent Infection Itself?
The company filed for FDA approval of a combination of Truvada with J&J's investigational non-nucleoside reverse transcriptase inhibitor TMC278, a regimen that could supplant Atripla.